Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
USD 36.0
(-7.98%)
USD 36.0
(-7.98%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 27.56 Million USD | -9.85% |
| 2022 | 30.58 Million USD | -95.12% |
| 2021 | 626.72 Million USD | 134.32% |
| 2020 | 267.45 Million USD | 0.0% |
| 2019 | - USD | -100.0% |
| 2018 | 117.51 Million USD | 0.0% |
| 2017 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 27.08 Million USD | 0.0% |
| 2024 Q2 | 26.19 Million USD | 0.0% |
| 2023 Q1 | 29.76 Million USD | -2.68% |
| 2023 Q2 | 29.11 Million USD | -2.17% |
| 2023 Q3 | 28.28 Million USD | -2.85% |
| 2023 FY | 27.56 Million USD | -9.85% |
| 2023 Q4 | 27.56 Million USD | -2.53% |
| 2022 Q4 | 30.58 Million USD | 651.38% |
| 2022 Q3 | 4.07 Million USD | -6.48% |
| 2022 Q2 | 4.35 Million USD | -99.31% |
| 2022 Q1 | 634.1 Million USD | 1.18% |
| 2022 FY | 30.58 Million USD | -95.12% |
| 2021 FY | 626.72 Million USD | 134.32% |
| 2021 Q1 | 270.75 Million USD | 1.23% |
| 2021 Q4 | 626.72 Million USD | 1.2% |
| 2021 Q3 | 619.26 Million USD | 125.9% |
| 2021 Q2 | 274.13 Million USD | 1.25% |
| 2020 Q2 | - USD | 0.0% |
| 2020 FY | 267.45 Million USD | 0.0% |
| 2020 Q3 | 264.13 Million USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q4 | 267.45 Million USD | 1.26% |
| 2019 Q2 | - USD | 0.0% |
| 2019 FY | - USD | -100.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q1 | - USD | -100.0% |
| 2018 Q4 | 117.51 Million USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | 117.51 Million USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2017 Q1 | 602 Thousand USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | -100.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ADC Therapeutics SA | 112.73 Million USD | 75.544% |
| Alto Neuroscience, Inc. | 151.33 Million USD | 81.783% |
| Annovis Bio, Inc. | - USD | -Infinity% |
| Ginkgo Bioworks Holdings, Inc. | 221.83 Million USD | 87.572% |
| Nuvation Bio Inc. | 2.03 Million USD | -1254.742% |
| Nuvation Bio Inc. | 2.03 Million USD | -1254.742% |
| Arcus Biosciences, Inc. | 110 Million USD | 74.937% |
| Theriva Biologics, Inc. | 162 Thousand USD | -16917.901% |
| Zymeworks Inc. | 22.46 Million USD | -22.742% |